Looking for outsized returns to supercharge your investment portfolio?
If you are, it could be worth checking out the two ASX 200 shares listed below that brokers are tipping to rise 30% to 40%.
Here's what they are recommending to clients:
Image source: Getty Images
Catapult Sports Ltd (ASX: CAT)
The first ASX 200 share that could rise strongly from current levels is Catapult Sports. It is a global leader in sports technology, providing wearable performance trackers and video analytics to professional teams.
During the first half of FY 2026, Catapult delivered further strong growth, reporting a 19% jump in annualised contract value (ACV) to US$115.8 million. This was underpinned by ACV retention at 95% and growth in its pro team customer base of 12% to 3,878 teams.
This caught the eye of analysts at Morgans. The good news is that they believe this strong growth can continue and are "estimating a ~20% ACV 3-year CAGR, reaching ~US$180m by FY28." The broker notes that Catapult has "expanded its service offering and opened up new key verticals assisting its penetration into a large addressable market of ~20k teams globally."
In response, Morgans has put a buy rating and $6.25 price target on its shares. Based on its current share price of $4.71, this represents a return of 33% for investors between now and this time next year. This would turn a $10,000 investment into over $13,000 in a year if everything were to go to plan.
Pro Medicus Ltd (ASX: PME)
Pro Medicus continues to redefine what world-class software looks like inside the global healthcare system. It has spent years perfecting the Visage platform, which allows radiologists to work faster and more accurately by streaming medical images at lightning speed.
With the increasing global demand for medical imaging, the shift to cloud-based workflows, and ongoing staff shortages in radiology departments, Pro Medicus appears well positioned to continue its strong growth long into the future. This is especially the case if its expansion into other ologies is successful.
Morgan Stanley recently put an overweight rating and $350.00 price target on its shares. Based on its current share price of $246.67, this implies potential upside of over 40% for investors over the next 12 months.
To put that into context, a $10,000 investment would turn into approximately $14,000 by this time next year if Morgan Stanley is on the money with its recommendation.
